Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment

Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment

Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy. Thus, changes in SV2A expression could be a critical factor in the response to LEV. Epilep...

Full description

Bibliographic Details
Main Authors: Itzel Jatziri Contreras-García, Gisela Gómez-Lira, Bryan Víctor Phillips-Farfán, Luz Adriana Pichardo-Macías, Mercedes Edna García-Cruz, Juan Luis Chávez-Pacheco, Julieta G. Mendoza-Torreblanca
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Brain Sciences
Subjects:
SV2A
levetiracetam
pharmacoresistance
VGAT
VGLUT
temporal lobe epilepsy
Online Access:https://www.mdpi.com/2076-3425/11/5/531

Internet

https://www.mdpi.com/2076-3425/11/5/531

Similar Items